LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION

<p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	O. D. Ostroumova [verfasserIn] M. L. Maksimov [verfasserIn] I. I. Kopchenov [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch ; Russisch

Erschienen:	2015

Schlagwörter:	артериальная гипертензия антигипертензивная терапия антагонисты кальция лерканидипин

Übergeordnetes Werk:	In: Рациональная фармакотерапия в кардиологии - Столичная издательская компания, 2012, 9(2015), 1, Seite 79-85
Übergeordnetes Werk:	volume:9 ; year:2015 ; number:1 ; pages:79-85

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.1234/1819-6446-2013-1-79-85

Katalog-ID:	DOAJ030246385

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ030246385
003	DE-627
005	20230307144617.0
007	cr uuu---uuuuu
008	230226s2015 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1234/1819-6446-2013-1-79-85 \|2 doi
035			\|a (DE-627)DOAJ030246385
035			\|a (DE-599)DOAJ81a64755100446a5a418d2253484a62d
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng \|a rus
050		0	\|a RM1-950
050		0	\|a RC666-701
100	0		\|a O. D. Ostroumova \|e verfasserin \|4 aut
245	1	0	\|a LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION
264		1	\|c 2015
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a <p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p<
650		4	\|a артериальная гипертензия
650		4	\|a антигипертензивная терапия
650		4	\|a антагонисты кальция
650		4	\|a лерканидипин
653		0	\|a Therapeutics. Pharmacology
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a M. L. Maksimov \|e verfasserin \|4 aut
700	0		\|a I. I. Kopchenov \|e verfasserin \|4 aut
773	0	8	\|i In \|t Рациональная фармакотерапия в кардиологии \|d Столичная издательская компания, 2012 \|g 9(2015), 1, Seite 79-85 \|w (DE-627)776633988 \|w (DE-600)2750390-2 \|x 22253653 \|7 nnns
773	1	8	\|g volume:9 \|g year:2015 \|g number:1 \|g pages:79-85
856	4	0	\|u https://doi.org/10.1234/1819-6446-2013-1-79-85 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/81a64755100446a5a418d2253484a62d \|z kostenfrei
856	4	0	\|u http://www.rpcardio.ru/jour/article/view/77 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1819-6446 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2225-3653 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 9 \|j 2015 \|e 1 \|h 79-85

Indexfelder

author_variant	o d o odo m l m mlm i i k iik
matchkey_str	article:22253653:2015----::ecndpnclimhnebokrfhtideeainepsiiiisnhte
hierarchy_sort_str	2015
callnumber-subject-code	RM
publishDate	2015
allfields	10.1234/1819-6446-2013-1-79-85 doi (DE-627)DOAJ030246385 (DE-599)DOAJ81a64755100446a5a418d2253484a62d DE-627 ger DE-627 rakwb eng rus RM1-950 RC666-701 O. D. Ostroumova verfasserin aut LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p< артериальная гипертензия антигипертензивная терапия антагонисты кальция лерканидипин Therapeutics. Pharmacology Diseases of the circulatory (Cardiovascular) system M. L. Maksimov verfasserin aut I. I. Kopchenov verfasserin aut In Рациональная фармакотерапия в кардиологии Столичная издательская компания, 2012 9(2015), 1, Seite 79-85 (DE-627)776633988 (DE-600)2750390-2 22253653 nnns volume:9 year:2015 number:1 pages:79-85 https://doi.org/10.1234/1819-6446-2013-1-79-85 kostenfrei https://doaj.org/article/81a64755100446a5a418d2253484a62d kostenfrei http://www.rpcardio.ru/jour/article/view/77 kostenfrei https://doaj.org/toc/1819-6446 Journal toc kostenfrei https://doaj.org/toc/2225-3653 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2015 1 79-85
spelling	10.1234/1819-6446-2013-1-79-85 doi (DE-627)DOAJ030246385 (DE-599)DOAJ81a64755100446a5a418d2253484a62d DE-627 ger DE-627 rakwb eng rus RM1-950 RC666-701 O. D. Ostroumova verfasserin aut LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p< артериальная гипертензия антигипертензивная терапия антагонисты кальция лерканидипин Therapeutics. Pharmacology Diseases of the circulatory (Cardiovascular) system M. L. Maksimov verfasserin aut I. I. Kopchenov verfasserin aut In Рациональная фармакотерапия в кардиологии Столичная издательская компания, 2012 9(2015), 1, Seite 79-85 (DE-627)776633988 (DE-600)2750390-2 22253653 nnns volume:9 year:2015 number:1 pages:79-85 https://doi.org/10.1234/1819-6446-2013-1-79-85 kostenfrei https://doaj.org/article/81a64755100446a5a418d2253484a62d kostenfrei http://www.rpcardio.ru/jour/article/view/77 kostenfrei https://doaj.org/toc/1819-6446 Journal toc kostenfrei https://doaj.org/toc/2225-3653 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2015 1 79-85
allfields_unstemmed	10.1234/1819-6446-2013-1-79-85 doi (DE-627)DOAJ030246385 (DE-599)DOAJ81a64755100446a5a418d2253484a62d DE-627 ger DE-627 rakwb eng rus RM1-950 RC666-701 O. D. Ostroumova verfasserin aut LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p< артериальная гипертензия антигипертензивная терапия антагонисты кальция лерканидипин Therapeutics. Pharmacology Diseases of the circulatory (Cardiovascular) system M. L. Maksimov verfasserin aut I. I. Kopchenov verfasserin aut In Рациональная фармакотерапия в кардиологии Столичная издательская компания, 2012 9(2015), 1, Seite 79-85 (DE-627)776633988 (DE-600)2750390-2 22253653 nnns volume:9 year:2015 number:1 pages:79-85 https://doi.org/10.1234/1819-6446-2013-1-79-85 kostenfrei https://doaj.org/article/81a64755100446a5a418d2253484a62d kostenfrei http://www.rpcardio.ru/jour/article/view/77 kostenfrei https://doaj.org/toc/1819-6446 Journal toc kostenfrei https://doaj.org/toc/2225-3653 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2015 1 79-85
allfieldsGer	10.1234/1819-6446-2013-1-79-85 doi (DE-627)DOAJ030246385 (DE-599)DOAJ81a64755100446a5a418d2253484a62d DE-627 ger DE-627 rakwb eng rus RM1-950 RC666-701 O. D. Ostroumova verfasserin aut LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p< артериальная гипертензия антигипертензивная терапия антагонисты кальция лерканидипин Therapeutics. Pharmacology Diseases of the circulatory (Cardiovascular) system M. L. Maksimov verfasserin aut I. I. Kopchenov verfasserin aut In Рациональная фармакотерапия в кардиологии Столичная издательская компания, 2012 9(2015), 1, Seite 79-85 (DE-627)776633988 (DE-600)2750390-2 22253653 nnns volume:9 year:2015 number:1 pages:79-85 https://doi.org/10.1234/1819-6446-2013-1-79-85 kostenfrei https://doaj.org/article/81a64755100446a5a418d2253484a62d kostenfrei http://www.rpcardio.ru/jour/article/view/77 kostenfrei https://doaj.org/toc/1819-6446 Journal toc kostenfrei https://doaj.org/toc/2225-3653 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2015 1 79-85
allfieldsSound	10.1234/1819-6446-2013-1-79-85 doi (DE-627)DOAJ030246385 (DE-599)DOAJ81a64755100446a5a418d2253484a62d DE-627 ger DE-627 rakwb eng rus RM1-950 RC666-701 O. D. Ostroumova verfasserin aut LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p< артериальная гипертензия антигипертензивная терапия антагонисты кальция лерканидипин Therapeutics. Pharmacology Diseases of the circulatory (Cardiovascular) system M. L. Maksimov verfasserin aut I. I. Kopchenov verfasserin aut In Рациональная фармакотерапия в кардиологии Столичная издательская компания, 2012 9(2015), 1, Seite 79-85 (DE-627)776633988 (DE-600)2750390-2 22253653 nnns volume:9 year:2015 number:1 pages:79-85 https://doi.org/10.1234/1819-6446-2013-1-79-85 kostenfrei https://doaj.org/article/81a64755100446a5a418d2253484a62d kostenfrei http://www.rpcardio.ru/jour/article/view/77 kostenfrei https://doaj.org/toc/1819-6446 Journal toc kostenfrei https://doaj.org/toc/2225-3653 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2015 1 79-85
language	English Russian
source	In Рациональная фармакотерапия в кардиологии 9(2015), 1, Seite 79-85 volume:9 year:2015 number:1 pages:79-85
sourceStr	In Рациональная фармакотерапия в кардиологии 9(2015), 1, Seite 79-85 volume:9 year:2015 number:1 pages:79-85
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	артериальная гипертензия антигипертензивная терапия антагонисты кальция лерканидипин Therapeutics. Pharmacology Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Рациональная фармакотерапия в кардиологии
authorswithroles_txt_mv	O. D. Ostroumova @@aut@@ M. L. Maksimov @@aut@@ I. I. Kopchenov @@aut@@
publishDateDaySort_date	2015-01-01T00:00:00Z
hierarchy_top_id	776633988
id	DOAJ030246385
language_de	englisch russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030246385</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307144617.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1234/1819-6446-2013-1-79-85</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030246385</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ81a64755100446a5a418d2253484a62d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. D. Ostroumova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">артериальная гипертензия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">антигипертензивная терапия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">антагонисты кальция</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">лерканидипин</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. L. Maksimov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Kopchenov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Рациональная фармакотерапия в кардиологии</subfield><subfield code="d">Столичная издательская компания, 2012</subfield><subfield code="g">9(2015), 1, Seite 79-85</subfield><subfield code="w">(DE-627)776633988</subfield><subfield code="w">(DE-600)2750390-2</subfield><subfield code="x">22253653</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:79-85</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1234/1819-6446-2013-1-79-85</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/81a64755100446a5a418d2253484a62d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.rpcardio.ru/jour/article/view/77</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1819-6446</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2225-3653</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">79-85</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	O. D. Ostroumova
spellingShingle	O. D. Ostroumova misc RM1-950 misc RC666-701 misc артериальная гипертензия misc антигипертензивная терапия misc антагонисты кальция misc лерканидипин misc Therapeutics. Pharmacology misc Diseases of the circulatory (Cardiovascular) system LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION
authorStr	O. D. Ostroumova
ppnlink_with_tag_str_mv	@@773@@(DE-627)776633988
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	22253653
topic_title	RM1-950 RC666-701 LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION артериальная гипертензия антигипертензивная терапия антагонисты кальция лерканидипин
topic	misc RM1-950 misc RC666-701 misc артериальная гипертензия misc антигипертензивная терапия misc антагонисты кальция misc лерканидипин misc Therapeutics. Pharmacology misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RM1-950 misc RC666-701 misc артериальная гипертензия misc антигипертензивная терапия misc антагонисты кальция misc лерканидипин misc Therapeutics. Pharmacology misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RM1-950 misc RC666-701 misc артериальная гипертензия misc антигипертензивная терапия misc антагонисты кальция misc лерканидипин misc Therapeutics. Pharmacology misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Рациональная фармакотерапия в кардиологии
hierarchy_parent_id	776633988
hierarchy_top_title	Рациональная фармакотерапия в кардиологии
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)776633988 (DE-600)2750390-2
title	LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION
ctrlnum	(DE-627)DOAJ030246385 (DE-599)DOAJ81a64755100446a5a418d2253484a62d
title_full	LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION
author_sort	O. D. Ostroumova
journal	Рациональная фармакотерапия в кардиологии
journalStr	Рациональная фармакотерапия в кардиологии
callnumber-first-code	R
lang_code	eng rus
isOA_bool	true
recordtype	marc
publishDateSort	2015
contenttype_str_mv	txt
container_start_page	79
author_browse	O. D. Ostroumova M. L. Maksimov I. I. Kopchenov
container_volume	9
class	RM1-950 RC666-701
format_se	Elektronische Aufsätze
author-letter	O. D. Ostroumova
doi_str_mv	10.1234/1819-6446-2013-1-79-85
author2-role	verfasserin
title_sort	lercanidipine, calcium channel blocker of the third generation: new possibilities in the treatment of arterial hypertension
callnumber	RM1-950
title_auth	LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION
abstract	<p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p<
abstractGer	<p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p<
abstract_unstemmed	<p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p<
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION
url	https://doi.org/10.1234/1819-6446-2013-1-79-85 https://doaj.org/article/81a64755100446a5a418d2253484a62d http://www.rpcardio.ru/jour/article/view/77 https://doaj.org/toc/1819-6446 https://doaj.org/toc/2225-3653
remote_bool	true
author2	M. L. Maksimov I. I. Kopchenov
author2Str	M. L. Maksimov I. I. Kopchenov
ppnlink	776633988
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1234/1819-6446-2013-1-79-85
callnumber-a	RM1-950
up_date	2024-07-03T13:51:00.512Z
_version_	1803566092668370944
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030246385</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307144617.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1234/1819-6446-2013-1-79-85</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030246385</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ81a64755100446a5a418d2253484a62d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. D. Ostroumova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.</p<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">артериальная гипертензия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">антигипертензивная терапия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">антагонисты кальция</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">лерканидипин</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. L. Maksimov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. I. Kopchenov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Рациональная фармакотерапия в кардиологии</subfield><subfield code="d">Столичная издательская компания, 2012</subfield><subfield code="g">9(2015), 1, Seite 79-85</subfield><subfield code="w">(DE-627)776633988</subfield><subfield code="w">(DE-600)2750390-2</subfield><subfield code="x">22253653</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:79-85</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1234/1819-6446-2013-1-79-85</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/81a64755100446a5a418d2253484a62d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.rpcardio.ru/jour/article/view/77</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1819-6446</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2225-3653</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">79-85</subfield></datafield></record></collection>
score	7.402237

Nicht das Richtige dabei?

Schreiben Sie uns!

LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?